BFM
CASI

Boothbay Fund Management’s CASI Pharmaceuticals CASI Stock Holding History

Boothbay Fund Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,686
Closed -$33K – 2266
2022
Q2 		$33K Hold
11,686
– – ﹤0.01% 2140
2022
Q1 		$95K Hold
11,686
– – ﹤0.01% 2110
2021
Q4 		$93K Hold
11,686
– – ﹤0.01% 1725
2021
Q3 		$139K Sell
11,686
-6,913
-37% -$93.5K ﹤0.01% 1718
2021
Q2 		$288K Buy
18,599
+2,404
+15% +$40.4K 0.01% 1310
2021
Q1 		$389K Hold
16,195
– – 0.01% 1079
2020
Q4 		$478K Sell
16,195
-3,470
-18% -$75.4K 0.02% 763
2020
Q3 		$301K Buy
19,665
+5,747
+41% +$108K 0.02% 803
2020
Q2 		$348K Hold
13,918
– – 0.02% 663
2020
Q1 		$284K Buy
+13,918
New +$332K 0.02% 579

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Boothbay Fund Management's CASI Position: Q3 2022 in Review

Boothbay Fund Management sold out of CASI Pharmaceuticals (CASI) in Q3 2022, closing a stake of 11,686 shares — an estimated $33K sold.

Boothbay Fund Management first reported a position in CASI in Q1 2020 and held it in 10 quarters. The position peaked at $478K in Q4 2020. 24 funds tracked by Wall St. Rank hold CASI as of Q3 2022.

  • Boothbay Fund Management reported no remaining CASI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 11,686 CASI Pharmaceuticals shares in Q3 2022, an estimated $33K.
  • Boothbay Fund Management first reported a position in CASI Pharmaceuticals in Q1 2020 and held it in 10 quarters.
  • Boothbay Fund Management's CASI Pharmaceuticals position peaked at $478K in Q4 2020.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.